Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.
|Articles|August 12, 2020
J&J offers eye care activity book for kids
Advertisement
Johnson & Johnson Vision Head of North America Professional Relations Carol L. Alexander, OD, FAAO, joins Optometry Times® Gretchyn M. Bailey, NCLC, FAAO, to chat about J&J’s
Advertisement
Related to this article
Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness.
From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry.
Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for managing near vision loss.
Enspryng is the first subcutaneous, at-home treatment option for TED and the first interleukin (IL)-6 receptor inhibitor approved in the indication.
Susan Gromacki, OD, MS, FAAO, FSLS, details one of her AAOpt 2026 sessions, titled "Advances in Contact Lens Care for the New Contact Lens Technologies."
Three researchers share the prize for discovering channelrhodopsin, a light-sensitive protein now being tested to restore vision in retinal disease.
Presenters from AAOpt26's research symposium share their findings, applications for optometric practice, and goals for future study.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours
2
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
3
FDA approves subcutaneous Enspryng for TED
4
Missed AAOpt 2026? Here are the highlights by specialty
5